Scandinavian Biopharma has entered into a Nordic distribution agreement with Emergent Travel Health for the oral typhoid vaccine Vivotif.
Typhoid fever is a severe and potentially life-threatening infection caused by the Salmonella bacteria.
Since 1st of January 2020 Scandinavian Biopharma is the local representative for Vivotif in Sweden, Norway, Denmark and Finland.
“We are really excited about our expanded collaboration with Emergent and to strengthen our vaccine portfolio with Vivotif®. This product perfectly supports our commitment to protect travellers from contracting serious diseases,” says Björn Sjöstrand, CEO of Scandinavian Biopharma.
Photo of Björn Sjöstrand: Scandinavian Biopharma